Human Papillomavirus (HPV) causes 5% of all cancers worldwide, and the first vaccine against HPV was approved in 2006. In this seminar, Dr. John Schiller provides an overview of HPV virus and infection, compares the three FDA approved vaccines against HPV, and explains the endpoints used in the clinical trials to prove vaccine efficacy. After a decade of using the vaccine, retrospective studies now allow us to evaluate the possibility of using single-dose vaccination, which could lead to an increase in the general use of the vaccine (implementation), and improve HPV-related cancer prevention.
In his second seminar, Schiller discusses the high efficacy of HPV vaccine, which is exceptionally good at producing neutralizing antibodies and also benefits from the low mutation rate of HPV. Coming to a better understanding of the efficacy of the HPV vaccine will provide evidence to support single-dose vaccination and aids in the development of new vaccines.
Dr. John Schiller is a National Institutes of Health (NIH) distinguished investigator and a professor at the National Cancer Institute at the NIH. Schiller completed his bachelor’s degree in molecular biology at the University of Wisconsin-Madison (1975), and received a doctorate degree in Microbiology at the University of Washington in Seattle (1982). Schiller continued his… Continue Reading